# Certara Appoints Jon Resnick as Chief Executive Officer
Canonical URL: https://biopharmsignal.com/news/CERT/certara-appoints-jon-resnick-as-chief-executive-officer
Ticker: CERT
Company: Certara
Source: Certara
Published: 2025-12-11 11:00 EST
Original Source URL: https://ir.certara.com
## Summary

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec.

## Article Body
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec.
## Recent Company News
- 2026-05-11 10:25 EST — [Certara Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CERT/certara-reports-first-quarter-2026-financial-results) — Source: Certara
- 2026-04-22 11:00 EST — [Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat](https://biopharmsignal.com/news/CERT/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat) — Source: Certara
- 2026-04-09 20:15 EST — [Certara to Report First Quarter 2026 Financial Results on May 11th, 2026](https://biopharmsignal.com/news/CERT/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026) — Source: Certara
- 2026-03-03 13:00 EST — [Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib](https://biopharmsignal.com/news/CERT/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib) — Source: Certara
- 2026-02-27 13:30 EST — [Certara to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CERT/certara-to-participate-in-upcoming-investor-conferences) — Source: Certara
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)